Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Semaglutide in type 2 diabetes with chronic kidney disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, semaglutide also significantly reduced the rate of eGFR decline (annual slope difference 1•16 mL/min per 1•73 m², 0•86-1•47), MACE (HR 0•82, 0•68-0•98), and all-cause mortality (HR 0•80, 0•67-0•95)”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [26]
In the citing paper
“Treatment with injectable semaglutide 1 mg once weekly reduced the relative risk for the composite primary outcome (ie, ≥50% eGFR decline, eGFR <15 mL/min per 1•73 m², dialysis or transplant, or death due to kidney disease or cardiovascular disease) by 24% compared with placebo (HR 0•76, 0•66-0•88).26”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [26]
In the citing paper
“Moreover, the GLP-1 receptor agonist, semaglutide reduced the risk of a composite kidney end point in a dedicated kidney outcome trial.11”
From The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity (2025) · cites this paper as [11]
In the citing paper
“semaglutide can reduce the progression of chronic kidney disease in patients with and without diabetes and even in those taking SGLT2 inhibitors [12–14].”
From New drugs for the treatment of obesity: do we need approaches to preserve muscle mass? (2025) · cites this paper as [13]
In the citing paper
“Once-weekly treatment with 1 mg semaglutide reduced the risk of the primary composite outcome by 24% and delayed the progression of kidney dysfunction over a period of 4 years (75).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [75]
35 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
Stevens, P. E., Ahmed, S. B., Carrero, J. J., Foster, B., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., Kazancıoğlu, R., et al. (2024) · Kidney International · doi:10.1016/j.kint.2023.10.018 · Cited by 8,530
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Bikbov, B., Purcell, C. A., Levey, A. S., Smith, M., Abdoli, A., Abebe, M., Adebayo, O. M., Afarideh, M., Agarwal, S. K., Agudelo-Botero, M., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30045-3 · Cited by 6,648
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Self-citationLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Self-citationEffect of finerenone on chronic kidney disease outcomes in type 2 diabetes
Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Nowack, C., Schloemer, P., Joseph, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2025845 · Cited by 2,935
Self-citationEmpagliflozin in Patients with Chronic Kidney Disease
The EMPA-KIDNEY Collaborative Group (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2204233 · Cited by 2,754
Cardiovascular events with finerenone in kidney disease and type 2 diabetes
Pitt, B., Filippatos, G., Agarwal, R., Anker, S. D., Bakris, G. L., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Schloemer, P., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110956 · Cited by 1,814
Self-citation
Cited by
Items 201–300 of 1,871
Incretin hormone agonists: Current and emerging pharmacotherapy for obesity management
Alhomoud, I. S., Talasaz, A. H., Chandrasekaran, P., Brown, R., Mehta, A., & Dixon, D. L. (2024) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.4607 · Cited by 28
GLP-1 physiology and pharmacology along the gut-brain axis
Beutler, L. R. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194744 · Cited by 35
“Third, there is mounting evidence that GLP-1RA therapy in patients with obesity and/or type 2 diabetes has cardiovascular (142, 143), renal (144), hepatic (145), and mortality benefits that are partially independent of weight loss (146).”
Triple Agonism Based Therapies for Obesity
Goldney, J., Hamza, M., Surti, F., Davies, M. J., & Papamargaritis, D. (2025) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-025-00770-z · Cited by 22
“…such evidence is available for retatrutide, therapies with established cardiovascular and renal benefits—such as semaglu - tide, supported by SUSTAIN-6 [5] and FLOW [57] trials in people with T2D, and the SELECT trial [58] in people with obesity - should be prioritised in populations with existing”
Tang, A. S. P., Hsu, J. T. Y., Chong, S. K. S., Quek, J., Shek, G., Sulaimi, F., Chan, K. E., Anand, V. V., Chong, B., Mehta, A., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02840-3 · Cited by 29
Qin, H., Yu, J., Yu, H., Zhou, C., Yuan, D., Wang, Z., Zhu, Z., Wei, G., Ou, P., Li, Z., et al. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2026.01.008 · Cited by 32
Taal, M. W., & Selby, N. M. (2024) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2024.08.002 · Cited by 26
Pathogenesis and Therapeutic Perspectives of Tubular Injury in Diabetic Kidney Disease: An Update
Geng, J., Ma, S., Tang, H. R., & Zhang, C. (2025) · Biomedicines · doi:10.3390/biomedicines13061424 · Cited by 31
“Similarly, compared to placebo, semaglutide treatment significantly lowered the risk of a composite of clinically important kidney outcomes and death from cardiovascular causes in patients with T2DM and CKD, further verifying the therapeutic effect of GLP-1RAs in DKD [195].”
Chronic Kidney Disease Prevalence and Awareness Among US Adults
Gong, J., Vaduganathan, M., & Wadhera, R. K. (2025) · JAMA Cardiology · doi:10.1001/jamacardio.2025.4581 · Cited by 30
The Use of Semaglutide in Patients With Renal Failure-A Retrospective Cohort Study
Long, J. J., Sahi, S. S., Lemke, A. I., Na, J., Valencia, O. A. G., Budhiraja, P., Wadei, H. M., Sudhindran, V., Benzo, R., Clark, M. M., et al. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.07.008 · Cited by 22
Kidney Disease as a Cardiovascular Disease Priority
Kotwal, S. S., & Perkovic, V. (2024) · Circulation · doi:10.1161/circulationaha.124.068242 · Cited by 24
Self-citationGlucagon-like peptide-1 receptor agonists and type 1 diabetes: a potential game changer?
Resnick, O., Bril, F., & Beauchamp, G. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1520313 · Cited by 27
Muzurović, E. M., Katsiki, N., Volčanšek, Š., Plescia, F., Rizzo, M., & Mantzoros, C. S. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156494 · Cited by 25
Carlucci, P. M., Cohen, B., Saxena, A., Belmont, M. H., Masson, M., Gold, H. T., Buyon, J. P., & Izmirly, P. (2024) · Rheumatology · doi:10.1093/rheumatology/keae547 · Cited by 22
Modern Challenges in Type 2 Diabetes: Balancing New Medications with Multifactorial Care
Caturano, A., Galiero, R., Rocco, M. P., Tagliaferri, G., Piacevole, A., Nilo, D., Lorenzo, G. D., Sardu, C., Vetrano, E., Monda, M., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12092039 · Cited by 28
“Additionally, newer trials such as the FLOW trial have shown the nephroprotective effects of semaglutide, including reductions in the progression to end-stage renal disease, renal mortality, and creatinine levels [64].”
BackgroundSiddiqui, H. F., Waqas, S. A., Batool, R. M., Salim, H., Minhas, A. M. K., Hasni, S. F., Alsaid, A., Sannino, A., Afzal, A. M., & Khan, M. S. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10523-0 · Cited by 25
Kidney Parameters with Tirzepatide in Obesity with or without Type 2 Diabetes
Heerspink, H. J. L., Friedman, A. N., Bjornstad, P., van Raalte, D. H., Cherney, D., Cao, D., Garcia-Pérez, L.-E., Stefanski, A., Turfanda, I., Bunck, M. C., et al. (2025) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000764 · Cited by 20
“12 In the FLOW trial, albuminuria was also reduced with semaglutide use.”
Marques, P. S., Travlos, C. K., Matias, P., Neves, J. S., Tsoukas, M. A., Mavrakanas, T. A., Joza, J. E., Ferreira, J. P., & Sharma, A. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102573 · Cited by 22
Transforming steatotic liver disease management: The emerging role of GLP-1 receptor agonists
Jensen, E., Israelsen, M. E., & Krag, A. A. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000561 · Cited by 25
“Additionally, liraglutide seemed to improve the fibrosis stage even though not reaching statistical”
BackgroundHeerspink, H. J. L., Lu, Z., Du, Y., Duffin, K. L., Coskun, T., Haupt, A., & Hartman, M. L. (2025) · Kidney International Reports · doi:10.1016/j.ekir.2025.03.049 · Cited by 23
Maintaining kidney health in aging societies: a JSN and ERA call to action
Ortíz, A., Kramer, A., Rychlík, I., Nangaku, M., Yanagita, M., Jager, K. J., Caskey, F. J., Stel, V. S., Kashihara, N., Kuragano, T., et al. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf068 · Cited by 25
“The mean age of participants in pivotal trials was > 60– 67 years and 16% were > 74–78 years of age, the range representing different trials [27 , 61 , 66 ].”
CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes
Schnell, O., Almandoz, J. P., Anderson, L., Barnard-Kelly, K. D., Battelino, T., Blüher, M., Busetto, L., Catrinou, D., Ceriello, A., Cos, X., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02700-0 · Cited by 24
“The use of SGLT2is and MRAs was permitted, and randomization was stratified according to SGLT2i use at baseline [64].”
InfluentialRossing, P. R., Bakris, G. L., Perkovic, V., Pratley, R. E., Tuttle, K. R., Mahaffey, K. W., Idorn, T., Belmar, N., Bosch‐Traberg, H., Rasmussen, S., et al. (2025) · Diabetes Care · doi:10.2337/dc25-0472 · Cited by 29
Self-citationScreening for advanced steatotic liver disease
Johansen, S., Åberg, F. O., Tsochatzis, E. A., & Krag, A. A. (2025) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(25)00097-4 · Cited by 20
Semaglutide: a key medication for managing cardiovascular-kidney-metabolic syndrome
MacIsaac, R. J. (2025) · Future Cardiology · doi:10.1080/14796678.2025.2511412 · Cited by 30
“Beyond its well-documented effects on glycemic control, including reduced risk of progression to diabetes, and weight loss in individuals with and without T2D [5–8], semaglutide has been shown to reduce major adverse CV events (MACE) in adults with and without T2D [9–13].”
InfluentialHaggag, A. Z., Xu, J., Butcher, L., Pagnussat, S., Davies, G., Lundqvist, S., Wang, W., van Zuydam, N. R., Nelander, K., Jha, A., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16047 · Cited by 22
“17,18 Most approved GLP-1 RAs are injectable peptides that require a cold supply chain and storage.”
Yepes, C. A., Cardenas-Moreno, I. C., Daza-Arnedo, R., Fériz, K., Yama-Mosquera, E., Rincón, A. R., Castillo, G. A., Suarez-Rodriguez, A. F., Carreño-Jiménez, J., & Builes-Montaño, C. E. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01722-x · Cited by 27
Anti-inflammatory effects of tirzepatide: a systematic review and meta-analysis
Masson, W., Lobo, M., Nogueira, J. P., Barbagelata, L., Touzas, P., & Frías, J. P. (2026) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-025-09991-4 · Cited by 21
Xia, M., Li, C., Zhang, Y., Wang, T., Zhang, C., Zhou, J., Zhu, X., Hong, H., Li, H., Qian, Z., et al. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103857 · Cited by 23
“From a therapeutic perspective, GLP-1R agonists are already approved for the treatment of type 2 diabetes and obesity, with well-established safety and pharmacokinetic profiles in humans [88].”
Kandel, R., Roy, P., & Singh, K. P. (2025) · Frontiers in Bioscience-Scholar · doi:10.31083/fbs38963 · Cited by 31
“N-acetylcysteine has demonstrated protective effects against kidney injury during AKI caused by contrast-induced nephrotoxicity, emphasizing the role of oxidative stress in renal damage [188].”
Upcoming drug targets for kidney protective effects in chronic kidney disease
Nardone, M., Yau, K., Kugathasan, L., Odutayo, A., Mohsen, M., Ouimet, J.-P., Sridhar, V. S., & Cherney, D. Z. I. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae216 · Cited by 26
“Semaglutide led to a 24% lower incidence of the primary renal composite endpoint of kidney failure, sustained 50% decline in eGFR, and cardiovascular and renal death [28 ].”
InfluentialSGLT2 inhibitors and GLP-1 receptor agonists: which is the best anti-frailty drug?
Mone, P., Ciccarelli, M., Jankauskas, S. S., et al. (2024) · The Lancet Healthy Longevity · doi:10.1016/j.lanhl.2024.08.001 · Cited by 18
Zannad, F. M., McGuire, D. K., & Ortíz, A. (2024) · Journal of Internal Medicine · doi:10.1111/joim.20050 · Cited by 23
“The aims of GLP-1 RA prescription are likely to be updated based on the results of the FLOW study [86].”
Kalayci, A., Januzzi, J. L., Mitsunami, M., Tanboga, I. H., Karabay, C. Y., & Gibson, C. M. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaf037 · Cited by 18
Nishida, K., Chrétien, B., Dolladille, C., Ebina, T., Aleksić, B., Cabé, N., Savey, V., Onoue, T., & Yatsuya, H. (2025) · Clinical Nutrition · doi:10.1016/j.clnu.2025.06.011 · Cited by 38
Individualized Risk of CKD Progression among US Adults
Tio, M. C., Butler, J., Zhu, X., Obi, Y., Yen, T. E., Kalantar‐Zadeh, K., Streja, E., Dossabhoy, N. R., Hall, M. E., & Shafi, T. (2024) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000377 · Cited by 21
“Post hoc analyses of recent landmark trials of kidney-preserving therapies 21,23,37 can provide this information and assess ef fi cacy in different strata of the CKD progression risk.”
Cherney, D. Z. I., Belmar, N., Bjornstad, P., Chacko, M. M., Gunnarsson, T. P., Hodgin, J. B., Kretzler, M., Pruijm, M. T., Schytz, P. A., & Tuttle, K. R. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf114 · Cited by 26
Self-citationAgarwal, R., Green, J. B., Heerspink, H. J. L., Mann, J. F. E., McGill, J. B., Mottl, A. K., Nangaku, M., Rosenstock, J., Vaduganathan, M., BRINKER, M. D., et al. (2025) · Diabetes Care · doi:10.2337/dc25-1673 · Cited by 26
Self-citationObesity as a Disease: A Primer on Clinical and Physiological Insights
Shah, A., Davarci, O. O., Chaftari, P., & Avenatti, E. (2025) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcvj.1515 · Cited by 26
Wu, H.-L., Chen, J., Cata, J. P., Hsieh, C.-H., Cherng, Y., & Tai, Y. (2025) · British Journal of Anaesthesia · doi:10.1016/j.bja.2025.08.003 · Cited by 22
Poulsen, C., Jesse, K., Carstensen, B., Frimodt‐Møller, M., Hansen, T. W., Persson, F., Vistisen, D., & Rossing, P. R. (2024) · Kidney International Reports · doi:10.1016/j.ekir.2024.09.010 · Cited by 21
Self-citationKarakasis, P., Patoulias, D., Rizzo, M., Fragakis, N., & Mantzoros, C. S. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16258 · Cited by 24
Siddiqi, T. J., Khan, M. S., Waqas, S. A., Spall, H. G. C. V., Shapiro, M. D., Fonarow, G. C., Januzzi, J. L., Afzal, A. M., Pandey, A., Butler, J., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.70048 · Cited by 20
Impact of GLP-1 Receptor Agonists on Psoriasis and Cardiovascular Comorbidities: A Narrative Review
Haran, K., Johnson, C., Smith, P. L., Venable, Z., Kranyak, A. C., Bhutani, T., Jeon, C., & Liao, W. J. (2024) · Psoriasis Targets and Therapy · doi:10.2147/ptt.s485061 · Cited by 34
“44,45 As with any new therapies, side effects in GLP-1RAs such as diarrhea, vomiting, abdominal pain, and pancreatitis must be balanced against the benefits.”
Diabetes and cardiovascular disease in older adults
Bilal, A., & Pratley, R. E. (2024) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.15259 · Cited by 21
Self-citationDasgupta, I., Zac‐Varghese, S., Chaudhry, K., McCafferty, K., Winocour, P. H., Chowdhury, T. A., Bellary, S., Goldet, G., Wahba, M. M., De, P., et al. (2024) · Diabetic Medicine · doi:10.1111/dme.15450 · Cited by 28
Nissen, S. E., Wolski, K., D’Alessio, D. A., Weerakkody, G. J., Kiljanski, J. I., Wiese, R. J., Pavo, I. J., Cariou, B., & Nicholls, S. J. (2026) · JAMA Cardiology · doi:10.1001/jamacardio.2026.0767 · Cited by 25
McIntyre, R. S., & Kwan, A. T. H. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2430306 · Cited by 23
Proglucagon-derived peptides: human physiology and therapeutic potential
Gasbjerg, L. S., Nielsen, C. K., Suppli, M. P., Grøndahl, M. F. G., Holst, J. J., Knop, F. K., Jeppesen, P. B., & Lund, A. (2025) · Physiological Reviews · doi:10.1152/physrev.00057.2024 · Cited by 22
The Expanding Scope of GLP-1 Receptor Agonists: Six Uses Beyond Diabetes
Sheth, K., Kim, S., Porterfield, L. R., Virani, S. S., Wadhwani, S., & Vaughan, E. M. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01319-6 · Cited by 21
“More recently, the FLOW trial, a dedicated kidney outcome trial in patients with T2DM and CKD, was terminated early due to overwhelming efficacy and mortality benefit [ 24].”
InfluentialTamilwanan, S., Aziz, Z., Rong, L. Y., Bitar, A. N., Zarzour, R. A., & Alshehade, S. A. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-04358-0 · Cited by 26
“While this approach provides broad applicability, it complicates direct comparisons between specific agents and optimal dosing strategies [78, 79].”
Romagnani, P., Tang, S. C. W., Weins, A., Huber, T. B., Osafo, C., & Anders, H. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00671-w · Cited by 30
“In patients with adaptive podocytopathies, treatment focuses on reducing glomerular hyperfiltration in the remaining nephrons by controlling the underlying aetiological factors, such as obesity, diabetes, salt-rich or protein-rich diets, or pre-eclampsia 156–160 .”
Pruijm, M. T., Belmar, N., Bjornstad, P., Cherney, D. Z. I., Das, V., Gunnarsson, T., Hodgin, J. B., Schytz, P. A., Tuttle, K. R., & Kretzler, M. (2025) · Kidney International · doi:10.1016/j.kint.2025.10.005 · Cited by 25
Self-citationPugliese, N. R., Paneni, F., Tricò, D., Bacca, A. V., De Biase, N., Dalpiaz, H., Mengozzi, A., Virdis, A., Ghiadoni, L., Taddei, S., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02778-6 · Cited by 16
GLP-1R agonists: recent advances, current gaps, and future challenges
Saran, A., Raisinghani, R., Paliwal, S., & Sharma, S. K. (2025) · Molecular Diversity · doi:10.1007/s11030-025-11195-6 · Cited by 19
Next-generation therapeutics for diabetic kidney disease
Yi, T. W., Sridhar, V. S., Scott, J., Nardone, M., & Cherney, D. Z. I. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-025-01042-0 · Cited by 29
Steven, S., Kuntić, M., Münzel, T. F., & Daiber, A. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100082 · Cited by 26
“264 GLP-1RA also confer antihypertensive effects, 265,266 potent renoprotection in T2DM patients with chronic kidney disease, 267 and neuroprotection against ischemic stroke.”
Sato, A., Rodríguez-Molina, D., Yoshikawa‐Ryan, K., Yamashita, S., Okami, S., Liu, F., Farjat, A. E., Oberprieler, N. G., Kovesdy, C. P., Kanasaki, K., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13175107 · Cited by 18
“However, a recent clinical trial has demonstrated their cardiovascular benefit and possible kidney benefit, making this medication a new potential option to treat people with DKD [9].”
BackgroundWeight Loss Blockbuster Development: A Role for Unimolecular Polypharmacology
Zhou, Q., Li, G., Hang, K., Li, J., Yang, D., & Wang, M. (2024) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-061324-011832 · Cited by 16
Jhu, J., Fang, Y., Huang, C., Liou, H., Chen, M., & Tsai, M. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14361 · Cited by 19
“The promising outcomes of the FLOW trial indicated that semaglutide may mitigate the onset of renal failure, a decline in the estimated glomerular fi ltration rate (eGFR) from baseline, and cardiovascular or renal mortality in patients with diabetic kidney disease 16 .”
Khan, M. S., & Lea, J. P. (2024) · BMC Nephrology · doi:10.1186/s12882-024-03652-5 · Cited by 19
“…showed that semaglu-tide treatment significantly reduced the risk of clinically important kidney outcomes and death from CV causes in patients with CKD associated with T2D [28] (Table 2), thus, representing a potential additional future treat-ment option for patients with CKD associated with T2D.”
BackgroundRe-evaluating the concept of remission in type 2 diabetes: a call for patient-centric approaches
Khunti, K., Papamargaritis, D., Aroda, V. R., Anjana, R. M., & Kashyap, S. R. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00134-2 · Cited by 22
Diabetes and Chronic Kidney Disease
Limonte, C. P., Pilla, S. J., & de Boer, I. H. (2024) · JAMA · doi:10.1001/jama.2024.24671 · Cited by 19
Samson, S. L., Vellanki, P., Blonde, L., Hirsch, I. B., Hoang, T. D., Isaacs, S. D., Izuora, K. E., Wang, C. C. L., Ooi, C. P., Padilla, B. I., et al. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.01.006 · Cited by 35
Mendonça, L., Moura, H., Castro‐Chaves, P., Neves, J. S., & Ferreira, J. P. (2024) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000584 · Cited by 22
“The coexistence of cardiovascular and kidney disease is common among patients with type 2 diabetes (T2D), obesity, or CKD. 1 In recent years, SGLT2 inhibitors (SGLT2i) and fi nerenone have demonstrated a reduction in the risk of cardio-kidney end points in these patients, leading to the inclusion of new recommendations…”
InfluentialMechanisms and treatment of obesity-related hypertension—Part 2: Treatments
Parvanova, A. I., Abbate, M., Reseghetti, E., & Ruggenenti, P. L. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf035 · Cited by 23
Adamczak, M., Kurnatowska, I., Naumnik, B., Stompór, T. P., Tylicki, L., & Krajewska, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312941 · Cited by 21
Fabry Disease: Insights into Pathophysiology and Novel Therapeutic Strategies
Thompson, S., Roy, A., Geberhiwot, T., Gehmlich, K., & Steeds, R. P. (2025) · Biomedicines · doi:10.3390/biomedicines13030624 · Cited by 24
Shokravi, A., Seth, J., Lu, N., & Mancini, G. B. J. (2025) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-025-00248-2 · Cited by 17
Obesity-Related Glomerulosclerosis—How Adiposity Damages the Kidneys
Zbrzeźniak, J., Winiarska, A., Perkowska‐Ptasińska, A., & Stompór, T. P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136247 · Cited by 23
“The trial was stopped after interim analysis because the risk of a primary outcome event was 24% lower in the semaglutide group than in the placebo [93].”
Xia, X., Niu, H., Xu, C., Liu, X., Zhang, G., & Ling, J. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.168102 · Cited by 19
Zhang, S., Sidra, F. N. U., Álvarez, C. A., Kinaan, M., Lingvay, I., & Mansi, I. A. (2024) · Nature Communications · doi:10.1038/s41467-024-54009-3 · Cited by 20
“Our fi nding of a signi fi cant reduction in CKD progression outcome in association with GLP1-RA use is also consistent with the fi ndings of the FLOW study 44 .”
GLP-1-based therapeutics for cardiorenal protection in metabolic diseases
Apperloo, E. M., Heerspink, H. J. L., van Raalte, D. H., & Muskiet, M. H. A. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf110 · Cited by 25
“GLP-1RA-induced effects on kidney outcomes in T2D were more definitively confirmed by the recent dedicated FLOW trial (NCT03819153) [47 ].”
van Mil, D., Vart, P., Chertow, G. M., Gansevoort, R. T., Rossing, P. R., Toto, R. D., Correa-Rotter, R., Langkilde, A. M., Sjöström, C. D., Wheeler, D. C., et al. (2024) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000000000550 · Cited by 20
“27 Finally, several immunomodulatory agents in development for IgA nephropathy have demonstrated clear proteinuria-reducing effects.”
Self-citationThe Global Kidney Patient Trials Network and the CAPTIVATE Platform Clinical Trial Design
Kotwal, S. S., Perkovic, V., Jardine, M., Kim, D., Shah, N. A., Lin, E., Coggan, S. E., Billot, L., Vart, P., Wheeler, D. C., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.49998 · Cited by 21
Self-citationBellos, I., Λάγιου, Π., Benetou, V., & Marinaki, S. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13206181 · Cited by 19
“…effects of GLP1-RA were recently confirmed by the FLOW trial, indicating that among patients with type 2 diabetes and chronic kidney disease, semaglutide therapy was associated with a significantly reduced risk of kidney disease progression, cardiovascular events, and overall mortality [12].”
SGLT2 inhibitors across the spectrum of chronic kidney disease: a narrative review
Sloan, L. A. (2024) · Postgraduate Medicine · doi:10.1080/00325481.2024.2418795 · Cited by 20
“In addition, the glucagon-like peptide-1 receptor agonist, semaglutide, has been shown to reduce kidney outcomes and CV death in patients with T2D and CKD [72].”
Liu, Q., Guo, S., Tong, Y., Li, Q., Baoxiang, Z., Wang, J., Wang, Y., Gao, W., & Zou, X. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70220 · Cited by 21
“195 This renal protective effect was similarly demonstrated with another GLP-1RA, efpeglenatide, which reduced the risk of composite renal outcomes by 32%.”
Chen, K.-Y., Chan, H.-C., & Chan, C.-M. (2025) · Asia-Pacific Journal of Ophthalmology · doi:10.1016/j.apjo.2025.100245 · Cited by 26
Mottelson, M., Helby, J., Nordestgaard, B. G., Ellervik, C., Mandrup-Poulsen, T. R., Petersen, J., Bojesen, S. E., & Glenthøj, A. B. (2024) · BMJ · doi:10.1136/bmj-2023-079147 · Cited by 22
Engineered GLP-1R-targeting nanoplatforms: multimodal therapeutics in human diseases
Zeng, J., Tang, X., Qin, D., Yu, L., Zhou, X., Chi, F., Mi, J., Pan, H., Wu, J., Huang, B., et al. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03677-4 · Cited by 28
Jorge, A. M., Patel, A. V., Zhou, B., Zhang, L., & Choi, H. K. (2025) · Arthritis & Rheumatology · doi:10.1002/art.43403 · Cited by 19
GLP-1-derived therapies and sarcopenia: plea for a specific focus on at risk special populations
Scheen, A. J. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101708 · Cited by 28
GLP-1 receptor agonists in IBD: exploring the crossroads of metabolism and inflammation
Migliorisi, G., Gabbiadini, R., Buono, A. D., Ferraris, M., Privitera, G., Petronio, L., Bertoli, P., Bezzio, C., & Armuzzi, A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1610368 · Cited by 26
“Recent studies suggest that GLP-1 RAs could improve renal function in patients with chronic kidney disease (CKD) and DM2 (33, 34).”
Personalized Care in CKD: Moving Beyond Traditional Biomarkers
McDonnell, T., Banks, R. E., Taal, M. W., Vuilleumier, N., & Kalra, P. A. (2025) · The Nephron journals/Nephron journals · doi:10.1159/000543640 · Cited by 22
“In the last 5 years, three new effective medication classes targeting proteinuria reduction have been licensed for CKD, demonstrating signi fi cant advancements in therapeutic options [17 – 19].”
The role of the intestinal microbiome in cognitive decline in patients with kidney disease
Wagner, C. A., Frey-Wagner, I. M., Ortíz, A., Unwin, R. J., Liabeuf, S., Suzumoto, Y., Iervolino, A., Stasi, A., Marzo, V. D., Gesualdo, L., et al. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae253 · Cited by 20
Sun, P., Wan, Z., & Liu, Y. (2026) · Medicine Bulletin · doi:10.1002/mdb2.70020 · Cited by 29
Rasouli, N., Arslan, E. G., Catarig, A., Houlind, K. C., Ludvik, B. H., Nordanstig, J., Sourij, H., Thomas, S., Verma, S., & Bonaca, M. P. (2025) · Diabetes Care · doi:10.2337/dc25-1082 · Cited by 18
The interplay between heart failure and chronic kidney disease
Lala, A., Levin, A., & Khunti, K. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16371 · Cited by 22
“91 Beyond their glucose-lowering effect, GLP-1 receptor agonists are hypothesised to reduce cardiovascular and kidney outcomes by impacting both inflammatory and fibrotic drivers.”
Borlaug, B. A., Holse, C., Jung, M. H., Lincoff, A. M., Mulvagh, S. L., Stærk‐Østergaard, J., Tuttle, K. R., & Petrie, M. C. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102712 · Cited by 25
Self-citationVelji-Ibrahim, J., Radadiya, D. K., Devani, K., Patel, H. K., Nathani, P., Hassan, C., Pugliese, N., Thompson, C., & Sharma, P. (2025) · Journal of Obesity · doi:10.1155/jobe/3897161 · Cited by 23
Koufakis, T., Vlahakos, D., Vlachopoulos, C., Kallistratos, E., Kotsa, K., Liberopoulos, E. N., Stefanidis, I., & Hatziagelaki, E. E. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-025-00761-w · Cited by 21
“Furthermore, recent studies have shown a reduction in the risk of progression of CKD in patients with diabetic nephropathy who receive GLP-1 RA therapy [36].”
Natale, P., Green, S. C., Tunnicliffe, D. J., Pellegrino, G., Toyama, T., & Strippoli, G. F. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015849.pub2 · Cited by 40
GLP-1RA precision medicine in people with type 2 diabetes: current insights and future prospects
Cardoso, P., Dennis, J., & Pearson, E. R. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194742 · Cited by 20
“FLOW, the only kidney outcome trial to date of a GLP-1RA, included people with T2D and chronic kidney disease and found a 24% lower risk with injectable semaglutide (HR 0.76, 95% CI 0.66 to 0.88) (18).”
InfluentialAsymptomatic Hyperuricemia and the Kidney: Lessons from the URRAH Study
Barnini, C., Russo, E., Leoncini, G., Ghinatti, M. C., Macciò, L., Piaggio, M., Viazzi, F. C., & Pontremoli, R. (2025) · Metabolites · doi:10.3390/metabo15010011 · Cited by 17
“…benefits have been demonstrated with sodium-glucose cotransporter 2 (SGLT-2) inhibitors in both diabetic and non-diabetic patients [8–10] and with nonsteroidal selective mineralocorticoid receptor antagonist [11] and glucagon-like peptide 1 receptor agonist (GLP1RA) [12] in patients with diabetes.”
Glycemic Targets and Prevention of Complications
Tsushima, Y., & Galloway, N. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae776 · Cited by 21
Chang, Y., Hsieh, M., Ju, P., & Chang, C. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70175 · Cited by 22
“5 However, this clinical success is shadowed by persistent concerns over potential neuropsychiatric side effects, 6 particularly depression and suicidality.”
Messing, M., Torres, J. A., Holznecht, N. J., & Weimbs, T. (2024) · Nutrients · doi:10.3390/nu16193281 · Cited by 19
“Similarly, a study on semaglutide in patients with T2D and CKD showed significant benefits, including a 24% reduction in major kidney disease events and a slower decline in eGFR [72].”
ResultMann, J. F. E., Marx, N., Deanfield, J. E., Emerson, S. S., Inzucchi, S. E., McGuire, D. K., Mulvagh, S. L., Pop-Busui, R., Poulter, N. R., Engelmann, M. D. M., et al. (2025) · Diabetes Care · doi:10.2337/dc25-1080 · Cited by 27
Self-citationInfante, M., Silvestri, F., Padilla, N., Pacifici, F., Pastore, D., Pinheiro, M. M., Caprio, M., Tesauro, M., Fabbri, A., Novelli, G., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041303 · Cited by 20
Zhang, M., Lin, C., Cai, X., Jiao, R., Bai, S., Li, Z., Lv, F., Yang, W., Liu, G., Yang, X., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16078 · Cited by 15
“23 Although combination therapy with SGLT2is and GLP-1RAs is recommended, the question remains: Is it more effective to use one drug or a combination of two for cardiorenal protection?”
Metadata
- Authors
- Perkovic, V., Tuttle, K. R., Rossing, P., Mahaffey, K. W., Mann, J. F. E., Bakris, G., Baeres, F. M. M., Idorn, T., Bosch-Traberg, H., Lausvig, N. L., & Pratley, R.
- Affiliations
- University of Copenhagen (DK)
- Novo Nordisk A/S, Søborg, Denmark.
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-07-11
- Volume
- 391
- Issue
- 2
- Pages
- 109-121
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4398781461
- Cited by
- 2,099
- References
- 23
- Citations by year
- 2026: 953 · 2025: 863 · 2024: 281
- FWCI
- 551.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Digital Access to Libraries (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Funders
- Novo Nordisk A/S
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- semaglutide, chronic kidney disease, type 2 diabetes, renal failure, estimated glomerular filtration rate decline, cardiovascular mortality, albuminuria, GLP-1 receptor agonists, renal protection, cardiovascular outcomes, albumin-creatinine ratio, kidney transplantation, dialysis, anemia of chronic kidney disease, diabetic nephropathy, SGLT2 inhibitors
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Double-Blind Method, Glucagon-Like Peptides, Female, Glomerular Filtration Rate, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Male, Middle Aged, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.